179 related articles for article (PubMed ID: 10852279)
21. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.
Gudbjornsson B; Juliusson UI; Gudjonsson FV
Ann Rheum Dis; 2002 Jan; 61(1):32-6. PubMed ID: 11779755
[TBL] [Abstract][Full Text] [Related]
22. Management of corticosteroid-induced osteoporosis.
Drug Ther Bull; 2010 Sep; 48(9):98-101. PubMed ID: 20810708
[TBL] [Abstract][Full Text] [Related]
23. Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention.
Duyvendak M; Naunton M; van Roon EN; Brouwers JR
J Clin Pharm Ther; 2011 Jun; 36(3):356-66. PubMed ID: 21545615
[TBL] [Abstract][Full Text] [Related]
24. Management of corticosteroid-induced osteoporosis.
Yeap SS; Hosking DJ
Rheumatology (Oxford); 2002 Oct; 41(10):1088-94. PubMed ID: 12364625
[TBL] [Abstract][Full Text] [Related]
25. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
[TBL] [Abstract][Full Text] [Related]
27. Management of corticosteroid-induced osteoporosis.
Adachi JD; Olszynski WP; Hanley DA; Hodsman AB; Kendler DL; Siminoski KG; Brown J; Cowden EA; Goltzman D; Ioannidis G; Josse RG; Ste-Marie LG; Tenenhouse AM; Davison KS; Blocka KL; Pollock AP; Sibley J
Semin Arthritis Rheum; 2000 Feb; 29(4):228-51. PubMed ID: 10707991
[TBL] [Abstract][Full Text] [Related]
28. Calcium and vitamin D therapy in corticosteroid bone loss: what is the evidence.
Sambrook PN
J Rheumatol; 1996 Jun; 23(6):963-4. PubMed ID: 8782123
[No Abstract] [Full Text] [Related]
29. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
Buckley LM; Hillner BE
J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
[TBL] [Abstract][Full Text] [Related]
30. [Management of corticosteroid-induced osteoporosis].
Orcel P
Presse Med; 2006 Oct; 35(10 Pt 2):1571-7. PubMed ID: 17028523
[TBL] [Abstract][Full Text] [Related]
31. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
[TBL] [Abstract][Full Text] [Related]
32. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate.
Jenkins EA; Walker-Bone KE; Wood A; McCrae FC; Cooper C; Cawley MI
Scand J Rheumatol; 1999; 28(3):152-6. PubMed ID: 10380836
[TBL] [Abstract][Full Text] [Related]
33. Referral patterns to an osteoporosis clinic for dermatology patients undergoing prolonged corticosteroid therapy.
Mowad C; Cohen SF; Flandry Fussell N; Martin RE; Ellison CA
J Am Acad Dermatol; 2018 Mar; 78(3):591-592. PubMed ID: 29447676
[No Abstract] [Full Text] [Related]
34. Corticosteroid-induced osteoporosis: a guide to optimum management.
Cranney A; Adachi JD
Treat Endocrinol; 2002; 1(5):271-9. PubMed ID: 15832482
[TBL] [Abstract][Full Text] [Related]
35. Use of a peripheral dexa measurement for osteoporosis screening.
Kirk JK; Nichols M; Spangler JG
Fam Med; 2002 Mar; 34(3):201-5. PubMed ID: 11922536
[TBL] [Abstract][Full Text] [Related]
36. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Adachi J; Cranney A; Goldsmith CH; Bensen WG; Bianchi F; Cividino A; Craig GL; Kaminska E; Sebaldt RJ; Papaioannou A
J Rheumatol; 1994 Oct; 21(10):1922-6. PubMed ID: 7837160
[TBL] [Abstract][Full Text] [Related]
37. Response to alendronate in osteoporosis after previous treatment with etidronate.
Fairney A; Kyd P; Thomas E; Wilson J
Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
[TBL] [Abstract][Full Text] [Related]
38. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic strategies for osteoporosis].
Chapurlat R; Delmas PD
Ann Med Interne (Paris); 2000 Oct; 151(6):471-6. PubMed ID: 11104926
[TBL] [Abstract][Full Text] [Related]
40. Prevention and treatment of corticosteroid-induced osteoporosis.
Iwamoto J; Takeda T; Sato Y
Yonsei Med J; 2005 Aug; 46(4):456-63. PubMed ID: 16127768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
